CD274 and neoplasm: Several potential response biomarkers have been evaluated, including PD-L1 expression on tumor cells, but also peripheral blood immune cells subsets, TCR sequencing, tumor immune infiltrate, HLA expression, expression profiles of genes involved in inflammation and specific genetic mutations [77,78,80].